The Sage Group

Company Profile

Peripheral artery disease and venous disease

THE SAGE GROUP LLC was founded in 2002 to focus on a then unknown, but widely prevalent cardiovascular problem, peripheral artery disease (PAD). PAD is also sometimes known as peripheral vascular disease (PVD) or peripheral arterial occlusive disease (PAOD)

THE SAGE GROUP offers a unique disease-based approach to consulting and market research. Focusing exclusively on peripheral arterial disease, THE SAGE GROUP has become the complete resource in all aspects of lower limb disease including company participants, drug and device therapies, new technologies and stem cells as well as economic costs of PAD, critical limb ischemia (CLI) and amputation.

THE SAGE GROUP developed the Diabetes Method, a population-based projection model, which is believed to provide the most accurate estimates of the number of people with PAD and CLI. The Diabetes Method also provides the basis for estimating the general prevalence of diabetic foot ulcers (DFU) as well as DFU prevalence by type: ischemic, neuroischemic and neuropathic.

Recently, the company‚Äôs lower limb research expanded into venous disease. Like PAD venous disease is widely prevalent, but remains underestimated, underdiagnosed and undertreated. Despite the fact that chronic venous disease is a progressive disease, which can result in venous ulcers, it is frequently dismissed as a “cosmetic” problem. The first venous publication focuses on chronic venous disease (CVD) epidemiology, costs and consequences.